Develops targeted cancer medicines, including antibody-drug conjugates, for patients with solid tumors such as ovarian, breast and endometrial cancers.
10-K for FY2025, filed Mar 5, 2026
10-Q for Q3 FY2026, filed Nov 10, 2026
−$6.8MView ↗
8-K, filed Nov 10, 2026
The Company continues to advance its proposed merger (the “Merger”) with Avere Therapeutics, Inc., a privately held biotechnology company…View ↗
From immune discovery to ADC development
The older report described an immune-focused discovery platform and immunomedicine pipeline; the latest centers development on antibody-drug conjugates for cancer.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 5, 2026
Earlier programs move toward partnering
The older report described active development of clinical oncology programs; the latest says NextCure is seeking partners for those programs.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 5, 2026In addition, we are seeking to partner our other clinical programs NC410 and NC525 and to pursue a partner or obtain third-party financing…View ↗
Competes with Merck &, Daiichi Sankyo, OnCusp Therapeutics, Hansoh Pharma, AbbVie, Genmab, AstraZeneca, BeiGene, GSK, and Day One Biopharmaceuticals
10-K for FY2025, filed Mar 5, 2026SIM0505 faces a competitive landscape of CDH6-targeted programs in clinical development, most notably raludotatug deruxtecan (R-DXd), a…View ↗
Loading...